ReviewJournal of molecular histology2006
DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.
Review in Journal of molecular histology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 72 citations in OpenAlex.
- Peptide aptamer sP10 targeting NPM1 attenuates liver fibrosis and hepatocellular carcinoma.Journal of translational medicine · 2026Article
- Nucleophosmin 1 proteins as potential therapeutic targets in non-communicable chronic inflammatory diseases: a review of pathophysiological mechanisms.Frontiers in cell and developmental biology · 2026Review
- Abnormal nuclear and nucleolar immunoreactivity of p16INK4a represents a frameshift alteration in CDKN2A: the E6H4 clone recognizes the "p14ARF::p16INK4a" chimeric protein.Virchows Archiv : an international journal of pathology · 2025Article
- Overexpression of βTrCP1 elicits cell death in cisplatin-induced senescent cells.Cell death & disease · 2025Article
- Exploring the genetic profiles linked to senescence in thyroid tumors: insights on predicting disease progression and immune responses.Frontiers in oncology · 2025Article
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.Acta neuropathologica · 2023Article
- AML-Related NPM Mutations Drive p53 Delocalization into the Cytoplasm with Possible Impact on p53-Dependent Stress Response.Cancers · 2021Article
- Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!Molecular and cellular biochemistry · 2021Review
- Epigenetic CRISPR Screens IdentifyCancer research · 2020Article
- Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.Journal of clinical medicine · 2020Review
- Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography.Scientific reports · 2018Article
- On the relationship status for Arf and NPM1 - it's complicated.The FEBS journal · 2018Article
- GLTSCR2 promotes the nucleoplasmic translocation and subsequent degradation of nucleolar ARF.Oncotarget · 2017Article
- GLTSCR2 is an upstream negative regulator of nucleophosmin in cervical cancer.Journal of cellular and molecular medicine · 2015Article
- Effects of lead on the morphology and structure of the nucleolus in the root tip meristematic cells of Allium cepa L.International journal of molecular sciences · 2014Article
- MYC cofactors: molecular switches controlling diverse biological outcomes.Cold Spring Harbor perspectives in medicine · 2014Review
- Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.Protein science : a publication of the Protein Society · 2013Review
- Impact of NPM, TFF3 and TACC1 on the prognosis of patients with primary gastric cancer.PloS one · 2013Article
- Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin.Oncogenesis · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The p53/p14ARF/mdm2 stress response pathway plays a central role in mediating cellular responses to oncogene activation, genome instability, and therapy-induced DNA damage. Abrogation of the pathway occurs in most if not all cancers, and may be essential for tumor development. The high frequency with which the pathway is disabled in cancer and the fact that the pathway appears to be incompatible with tumor cell growth, has made it an important point of focus in cancer research and therapeutics development. Recently, Nucleophosmin (NPM, B23, NO38 and numatrin), a multifunctional nucleolar protein, has emerged as a p14ARF binding protein and regulator of p53. While complex formation between ARF and NPM retains ARF in the nucleolus and prevents ARF from activating p53, DNA damaging treatments promote a transient subnuclear redistribution of ARF to the nucleoplasm, where it interacts with mdm2 and promotes p53 activation. The results add support to a recently proposed model in which the nucleolus serves as a p53-uspstream sensor of stress, and where ARF links nucleolar stress signals to nucleoplasmic effectors of the stress response. A better understanding of ARF's nucleolar interactions could further elucidate the regulation of the p53 pathway and suggest new therapeutic approaches to restore p53 function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.